Your browser doesn't support javascript.
loading
Cost-effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain.
Ginestal, Ricardo; Rubio-Terrés, Carlos; Morán, Olga Durán; Rubio-Rodríguez, Darío; Los Santos, Heidi De; Ordoñez, Cristina; Sánchez-Magro, Isabel.
Affiliation
  • Ginestal R; Hospital Clínico San Carlos, Neurology Department, C/ Prof Martín Lagos, 28040 Madrid, Spain.
  • Rubio-Terrés C; HEALTH VALUE, HE Department, C/ Virgen de Aránzazu, 21, 28034 Madrid, Spain.
  • Morán OD; Merck, SLU, C/ María de Molina, 40, 28006 Madrid, Spain, an affiliate of Merck KGaA.
  • Rubio-Rodríguez D; HEALTH VALUE, HE Department, C/ Virgen de Aránzazu, 21, 28034 Madrid, Spain.
  • Los Santos H; Merck, SLU, C/ María de Molina, 40, 28006 Madrid, Spain, an affiliate of Merck KGaA.
  • Ordoñez C; Merck, SLU, C/ María de Molina, 40, 28006 Madrid, Spain, an affiliate of Merck KGaA.
  • Sánchez-Magro I; Merck, SLU, C/ María de Molina, 40, 28006 Madrid, Spain, an affiliate of Merck KGaA.
J Comp Eff Res ; 12(2): e220193, 2023 02.
Article in En | MEDLINE | ID: mdl-36705064
ABSTRACT

Aim:

To analyze the cost-effectiveness of treatment of relapsing remitting multiple sclerosis (RRMS) with cladribine tablets (CladT) and dimethyl fumarate (DMF) from the perspective of the Spanish National Health System (NHS).

Methods:

A probabilistic Markov model (second-order Monte Carlo simulation) with a 10-year time horizon and annual Markov cycles was performed.

Results:

CladT was the dominant treatment, with lower costs (-74,741 € [95% CI -67,247; -85,661 €]) and greater effectiveness (0.1920 [95% CI -0.1659; 0.2173] QALY) per patient, compared with DMF. CladT had a 95.1% probability of being cost-effective and a 94.1% chance of being dominant compared with DMF.

Conclusion:

CladT is the dominant treatment (lower costs, with more QALYs) compared with DMF in the treatment of RRMS in Spain.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / Multiple Sclerosis Type of study: Health_economic_evaluation Limits: Humans Country/Region as subject: Europa Language: En Journal: J Comp Eff Res Year: 2023 Document type: Article Affiliation country: Spain
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / Multiple Sclerosis Type of study: Health_economic_evaluation Limits: Humans Country/Region as subject: Europa Language: En Journal: J Comp Eff Res Year: 2023 Document type: Article Affiliation country: Spain